Bleomycin Hydrochloride Drug Asset Due Diligence Report 2026

This Bleomycin Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

178

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Bleomycin Hydrochloride can convert its Glycopeptide antibiotic profile and Not disclosed biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Bleomycin Hydrochloride (query alias: bleomycin)
Modality / target	Glycopeptide antibiotic; Not disclosed; DNA synthesis inhibitors
Highest global status	Approved
Originator	Bristol Myers Squibb Co.
Active developers	Nippon Kayaku Co., Ltd., Bristol Myers Squibb Co.

The MCP disease footprint includes Germinoma, Neoplasms, Embryonal Carcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07197541	Phase 4	Active, not recruiting	200	Skin lesions completely cleared
NCT07201766	Not Applicable	Not yet recruiting	104	The Efficacy in terms of POSAS SCAR SCALE of Intralesional Bleomycin as compared to 5-fluorouracil (5-FU) and Triamcinolone Acetonide(TAC) for the treatment of Keloids: A Randomized Control Trial
ChiCTR2500113466	Not Applicable	Completed	13	Lesion area

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

FRONTLINE ABVD IS STILL FEASIBLE IN ADVANCED STAGE HODGKIN LYMPHOMA AS EARLY STAGE: A RETROSPECTIVE REAL-WORLD COHORT STUDY FROM TURKEY

Not Applicable; n=95; evaluation: Positive. Reported fields: Complete response rates = 95.2 % ; Complete response rates = 97.0 %

Non-melanoma skin cancer treated with electrochemotherapy: Clinical outcomes and tolerability

Not Applicable; n=16; evaluation: Positive. Reported fields: Adverse Event: Erythema = grade 1

Reproductive outcomes after fertility sparing surgery in malignant ovarian germ cell tumors- retrospective study at state cancer institute

Not Applicable; n=72; evaluation: Positive. Reported fields: Conception rate(chemotherapy) = 60.0 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Bleomycin Hydrochloride addresses Germinoma, Neoplasms, Embryonal Carcinoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Glycopeptide antibiotic—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 0 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
No matched asset transaction returned.

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Discovey of bleomycin hydrochloride for treating coronaviridae family of virus”. The milestone feed surfaced a patent-application signal described as “Bleomycin-based compositions and use thereof for treating loose skin and fatty tissue”. The milestone feed surfaced a patent-application signal described as “A bleomycin preparation for use against skin tumours”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO